Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues

Apellis Pharmaceuticals (APLS) reported fourth-quarter 2024 loss of 29 cents per share, narrower than the Zacks Consensus Estimate of a loss of 39 cents. The company had incurred a loss of 73 cents in the year-ago quarter.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Total revenues in the fourth quarter amounted to $212.5 million and surpassed the Zacks Consensus Estimate of$196 million. In the year-ago quarter, the company had reported revenues of $146.4 million.The top line jum ...